Alfonso Iorio - McMaster Experts

Affiliations

Faculty of Health Sciences, McMaster University
Member, McMaster Centre for Transfusion Research (MCTR), Faculty of Health Sciences
Member, Michael G. DeGroote Cochrane Canada Centre at McMaster, Faculty of Health Sciences
Professor, Health Research Methods, Evidence, and Impact, Faculty of Health Sciences
Joint Appointment, Medicine, Faculty of Health Sciences
Director, Health Information Research Unit (HIRU), Faculty of Health Sciences

Scholarly Activity in McMaster Experts

Co-author Network

Scholarly Activity
Teaching
Contact
View All

selected scholarly activity

chapters
- Non-Anticoagulant Actions of Glycosaminoglycans. 101-112. 1996
conferences
- Test–retest reliability of a mobile application of the patient reported outcomes burdens and experiences (PROBE) study. Haemophilia. 702-708. 2024
- Comparing inhibitor development in (plasma derived vs. recombinant) FVIII/FIX concentrates in severe haemophilia: Reporting on 1392 PUPs from EUHASS and canadian registries. Haemophilia. 100-100. 2024
- International data integration program of the WFH world bleeding disorders registry: bringing europe data to the global stage. Haemophilia. 56-57. 2024
- Experience with Emicizumab Among People with Hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry. Blood. 1240-1240. 2023
- A COMPARATIVE STUDY OF DIFFERENT METHODS OF HANDLING MISSING DATA IN PATIENT REPORTED OUTCOMES, BURDENS AND EXPERIENCES (PROBE) SCORE ALGORITHM AMONG PEOPLE WITH HEMOPHILIA. American Journal of Hematology. E48-E48. 2023
- BUILDING A GLOBAL RESOURCE FOR THE LONG-TERM FOLLOW-UP OF HEMOPHILIA PATIENTS TREATED WITH GENE THERAPY: COLLABORATION BETWEEN THE WORLD FEDERATION OF HEMOPHILIA AND NATIONAL REGISTRIES. Haemophilia. 104-104. 2023
- COLLABORATION FOR THE LONG-TERM FOLLOW-UP OF PEOPLE WITH HEMOPHILIA TREATED WITH GENE THERAPY: WORLD FEDERATION OF HEMOPHILIA- AMERICAN THROMBOSIS AND HEMOSTASIS NETWORK. American Journal of Hematology. E23-E23. 2023
- TEST-RETEST RELIABILITY ANALYSIS OF THE PATIENT REPORTED OUTCOMES BURDENS AND EXPERIENCES (PROBE) STUDY. Haemophilia. 62-63. 2023
- Real-World Outcomes of Emicizumab in Hemophilia A with or without FVIII Inhibitors from the Canadian Hemophilia Bleeding Disorder Registry. Blood. 8465-8467. 2022
- COST-EFFECTIVENESS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS. Value in Health. S428-S428. 2022
- Comparison of change in number of identified people with haemophilia A and factor VIII use per patient over time. Haemophilia. 38-39. 2022
- Empowering people with haemophilia to take control of their care and treatment through myWBDR and myPROBE-A patient-reported outcomes tool for achieving a 360-degree patient-centred evaluation. Haemophilia. 80-81. 2022
- Feasibility of integrating PROBE (patient reported outcomes, burdens and experiences) into a clinical care pathway to facilitate transformation to a value-based health care model in haemophilia. Haemophilia. 87-88. 2022
- Integration of the Mexican Registry of Coagulopathies (RMC) with PROBE. Haemophilia. 10-11. 2022
- Prevalence of selected bleeding and thrombotic events in persons with congenital haemophilia versus the general non-haemophilia population. Haemophilia. 32-33. 2022
- Using the World Federation of Haemophilia gene therapy registry for the long-term follow-up of haemophilia patients treated with gene therapy. Haemophilia. 34-36. 2022
- WFH world bleeding disorders registry highlights gaps in haemophilia diagnosis and management. Haemophilia. 33-34. 2022
- CANADIAN CLINICAL EXPERIENCE ON SWITCHING FROM OCTOCOG ALFA TO EXTENDED-HALF-LIFE FVIII DAMOCTOCOG ALFA PEGOL IN PATIENTS WITH SEVERE HAEMOPHILIA A. Haemophilia. 43-43. 2022
- THE WORLD FEDERATION OF HEMOPHILIA GENE THERAPY REGISTRY - A GLOBAL RESOURCE FOR THE LONG-TERM FOLLOW-UP OF HEMOPHILIA PATIENTS TREATED WITH GENE THERAPY. Haemophilia. 97-98. 2022
- Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry. Blood. 347-347. 2021
- Perioperative Outcomes Associated with Inhibitor Status in Patients with Hemophilia - a Retrospective Cohort Study. Blood. 4990-4990. 2021
- ANALYSIS OF HEMOPHILIA PATIENT IDENTIFICATION IN DIFFERENT ECONOMIC SETTINGS. Haemophilia. 18-19. 2021
- EQUITY IN THE USE OF PROPHYLAXIS IN CHILDREN WITH SEVERE HEMOPHILIA. Haemophilia. 20-20. 2021
- THE WORLD FEDERATION OF HEMOPHILIA GENE THERAPY REGISTRY. Haemophilia. 132-133. 2021
- WORLD BLEEDING DISORDERS REGISTRY SHOWCASES DISPARITIES IN HEMOPHILIA CARE AROUND THE WORLD. Haemophilia. 136-136. 2021
- Analysis of Hemophilia a Outcomes and Treatment Patterns Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry. Blood. 37-38. 2020
- Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database. Blood. 21-22. 2020
- Potency-Adjusted Analyses of a Head-to-Head Pharmacokinetic Study of Damoctocog Alfa Pegol (BAY 94-9027) and Efmoroctocog Alfa (rFVIIIFc) in Patients with Severe Hemophilia A. Blood. 24-25. 2020
- Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments. Blood. 22-23. 2020
- Comparative PK evaluation of SHL vs EHL by non-compartmental and compartmental population PK analysis in patients with severe and moderate HA. Haemophilia. 63-63. 2020
- Data is the new currency: The World Bleeding Disorders Registry Data Quality Accreditation Program. Haemophilia. 94-95. 2020
- Education in people with Hemophilia - Insights from the PROBE Study. Haemophilia. 132-132. 2020
- International Standard Set of Health Outcomes that matter for people living with hemophilia. Haemophilia. 60-61. 2020
- What the future might look like-The PROBE Study. Haemophilia. 41-41. 2020
- ASSESSING A POPULATION PHARMACOKINETIC MODEL OF A PLASMA-DERIVED, VON WILLEBRAND FACTOR-CONTAINING FVIII CONCENTRATE FOR BAYESIAN FORECASTING IN LOW DOSE SCENARIOS. Haemophilia. 49-49. 2020
- DEVELOPMENT AND TESTING OF THE ONLINE PROBE SURVEY AND THE MYPROBE APP AND INTEGRATION WITH THE CANADIAN BLEEDING DISORDER REGISTRY. Haemophilia. 76-77. 2020
- INTERNATIONAL STANDARD SET OF HEALTH OUTCOMES THAT MATTER FOR PEOPLE LIVING WITH HEMOPHILIA. Haemophilia. 119-119. 2020
- PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS. Haemophilia. 88-89. 2020
- REPORT ON THE ANNUAL GLOBAL SURVEY-20 YEARS ON AND MORE INFORMATIVE. Haemophilia. 22-22. 2020
- THE WORLD BLEEDING DISORDERS REGISTRY CELEBRATES 2 YEARS!. Haemophilia. 103-104. 2020
- Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics Are Similar across Different FVIII Products in Patients with Severe Hemophilia A. Blood. 3637-3637. 2019
- Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products. Blood. 2405-2405. 2019
- Routine Double Filtration Plasmapheresis Affects Hemostatic Proteins and Prolongs Clotting Tests. Blood. 1178-1178. 2019
- Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization. Journal of Pharmacokinetics and Pharmacodynamics. 411-426. 2019
- Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients. Journal of Pharmacokinetics and Pharmacodynamics. 427-438. 2019
- PROSPECTIVE STUDY OF THE IMMUNOLOGICAL RES PONSE TO FACTOR VIII IN SEVERE HEMOPHILIA A PATIENTS DURING IMMUNE TOLERANCE INDUCTION TREATMENT. Haematologica. 16-16. 2019
- coreHEM, a Multistakeholder Core Outcome Set Project for Gene Therapy in Hemophilia. Molecular Therapy. 277-277. 2019
- ASSESSMENT OF PHARMACOKINETIC BAYESIAN PREDICTIONS IN HEMOPHILIA B USING LIMITED SAMPLING ANALYSIS.. Clinical Pharmacology and Therapeutics. S89-S89. 2019
- Part-time employment and early retirement in people with severe haemophilia: Insights from the PROBE study. Haemophilia. 137-138. 2019
- Predictors for acute and chronic pain in patients with severe haemophilia in the PROBE cohort. Haemophilia. 76-76. 2019
- The WFH world bleeding disorders registry. Haemophilia. 79-79. 2019
- The Web-Accessible Population Pharmacokinetics Service-Hemophilia (WAPPS-HEMO) contribution to tailoring treatment in children: Examples for hemophilia A and B. Haemophilia. 29-29. 2019
- Using individual pharmacokinetic parameters on octocog alfa to predict individual pharmacokinetic parameters on efmoroctocog alfa in persons with hemophilia A. Haemophilia. 110-110. 2019
- Creating a Population Model for PK-Tailored Dosing Using Real-World Data from the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) Platform. Blood. 1191-1191. 2018
- Observational Study of Real-World Factor Utilization and Health Outcomes in Patients with Hemophilia in Canada. Blood. 4813-4813. 2018
- Prospective Study of the Immunological Mechanisms of Immune Tolerance Induction in Severe Haemophilia a Patients with Inhibitors: Preliminary Analysis of a Multi-Center Longitudinal Study. Blood. 3781-3781. 2018
- Comparative assessment of the performance of pharmacokinetic tools for prophylactic dosing of anti-hemophilic factor recombinant plasma/albumin-free method (rAHF-PFM) concentrate in patients with Hemophilia A. Haemophilia. 90-90. 2018
- First Steps in Choosing Appropriate Instruments/Measurements for a Core Outcome Set: An Example from Corehem. Value in Health. S212-S212. 2018
- The PROBE Data Dashboard - A new tool for real-time data visualization and analysis of patient reported outcomes. Haemophilia. 181-182. 2018
- The PROBE Study - Global burden of bleeding from the mouth in Haemophilia - a call to action. Haemophilia. 66-67. 2018
- The WFH World Bleeding Disorders Registry. Haemophilia. 37-37. 2018
- coreHEM: A multi-stakeholder approach to developing a core outcome set for gene therapy in hemophilia. Haemophilia. 81-81. 2018
- eLearning of pharmacokinetic monitoring in hemophilia with application in the clinical practice. Haemophilia. 137-137. 2018
- Comparative assessment of the performance of pharmacokinetic tools for prophylactic dosing of factor VIII concentrate in patients with hemophilia A. Haemophilia. 50-51. 2018
- Occurrence and impact of pain among patients living with hemophilia: An analysis from the patient reported outcomes, burdens and experiences (PROBE) study. Haemophilia. 26-27. 2018
- Online course of pharmacokinetic monitoring in hemophilia with application in the clinical practice. Haemophilia. 92-92. 2018
- Perioperative management for patients with congenital factor XI deficiency. Haemophilia. 26-26. 2018
- The WFH world bleeding disorders registry. Haemophilia. 67-67. 2018
- Burden of Comorbid Diseases in Patients with Hemophilia: The Cross-Sectional Analysis of the Patient Reported Outcomes, Burden and Experiences (PROBE) Study. Blood. 2017
- Comparative Assessment of the Performance of Pharmacokinetic Tools for Prophylactic Dosing of Antihemophilic Factor Recombinant Plasma/Albumin-Free Method (rAHF-PFM) Concentrate in Patients with Hemophilia A. Blood. 2017
- Evaluation of Plasma-Derived FVII Efficacy for the Treatment of Bleeding in a Murine Model of Hemophilia a. Blood. 2017
- Population Pharmacokinetics Profiling to Tailor Prophylaxis in Hemophilia a Patients: A Pilot Feasibility Study. Blood. 2017
- Sexual Health in Patients with Hemophilia; The Insights from the Patient Reported Outcomes, Burdens and Experiences (PROBE) Study. Blood. 2017
- The Development of the World Bleeding Disorders Registry Pilot Phase. Haemophilia. 80-80. 2017
- An individual participant data meta-analysis of 13 randomized trials to evaluate the impact of prophylactic use of heparin in oncological patients. Blood. 2017
- Methodology and Systematic Review of the Literature for the Mcmaster RARE-Best Practice Clinical Practice Guideline on Diagnosis and Management of the Catastrophic Antiphospholipid Syndrome. Arthritis & Rheumatology. 2017
- THU0561 Clinical practice guideline for diagnosis and management of catastrophic antiphospholipid syndrome. Annals of the Rheumatic Diseases. 2017
- The Khorana score for the prediction of venous thromboembolism in patients with solid cancer: an individual patient data meta-analysis. Journal of Thrombosis and Haemostasis. 2017
- Clinical and Biological Determinants of Bleeding Manifestation in Congenital Factor XI Deficiency; A Systematic Review. Blood. 1407-1407. 2016
- Installing FVIII-Specific Tolerance in Hemophilia Via Engagement of the Aryl Hydrocarbon Receptor By Tryptophan Derivatives. Blood. 2563-2563. 2016
- Interim Canadian Data from a Prospective, Observational Study of Routine Clinical Use of a Von Willebrand Factor Concentrate (Wilate®). Blood. 2593-2593. 2016
- Perioperative Management for Congenital Factor XI Deficiency; A Systematic Review. Blood. 3796-3796. 2016
- Perioperative Management of Von Willebrand Disease, a Systematic Review and Meta-Analysis. Blood. 1408-1408. 2016
- Rwd Study for Epidemiology and Characteristics of Patients with Multiple Myeloma in Italy. Blood. 5693-5693. 2016
- Test-Retest Reliability Analysis of the Patient Reported Outcomes Burdens and Experiences (PROBE). Blood. 5964-5964. 2016
- The Effect of Platelet Transfusion on Death in the Intensive Care Unit. Blood. 3850-3850. 2016
- Warfarin Resumption after Intracranial Hemorrhage: A Systematic Review and Meta-Analysis. Blood. 3821-3821. 2016
- NHF-MCMASTER GUIDELINE ON CARE MODELS FOR HEMOPHILIA MANAGEMENT. American Journal of Hematology. E428-E429. 2016
- Hemophilia research and clinical care needs: Regional variation in future priorities. Haemophilia. 51-51. 2016
- Home therapy consensus in an under resourced hemophilia setting. Haemophilia. 127-127. 2016
- Measuring the quality of hemophilia care across different settings: a set of performance indices derived from demographics data. Haemophilia. 26-26. 2016
- The patient reported outcomes burdens and experiences (PROBE) study phase 1 methodology and feasibility results. Haemophilia. 118-119. 2016
- When health care professionals express themselves: results overview of the qualitative phase of Hero initiative. Haemophilia. 13-13. 2016
- The patient reported outcome burdens and experiences (PROBE) study - phase 1 results show PROBE study methodology feasible. Journal of Thrombosis and Haemostasis. 47-47. 2016
- Evidence Based Haemophilia Care - Current Status and Where to Go?. Haemophilia. 6-6. 2016
- Haemophilia Research and Clinical Care Needs: Assessing Future Priorities. Haemophilia. 42-43. 2016
- Health Status of Elderly Persons with Hemophilia Compared with the General Population: The Sphera Study. Haemophilia. 29-30. 2016
- Nonacog Alfa as Prophylaxis in Moderately Severe to Severe (FIX:C <= 2%) Hemophilia B Patients: Identifying Clinical Predictors of Response. Haemophilia. 69-69. 2016
- The Patient Reported Outcomes, Burdens, and Experiences (Probe) Phase 1 Study Methodology and Feasibility. Haemophilia. 43-44. 2016
- Bleeding in Patients Receiving Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis. Blood. 1120-1120. 2015
- Outcomes of Low-Molecular-Weight Heparintreatment for Venous Thromboembolism in Patients with Primary and Metastatic Brain Tumors. Blood. 428-428. 2015
- Safety and Effectiveness of Desmopressin for the Management of Delivery and Major Surgery in Patients with Mild-Moderate Von Willebrand Disease: Final Analysis of the Prodeswil Study. Blood. 2015
- Switching to Warfarin after 6-Month Completion of Anticoagulant Treatment for Cancer-Associated Thrombosis. Blood. 430-430. 2015
- Study Design: A Critical Aspect of Research. Haemophilia. E527-E527. 2015
- Web Accessible Population Pharmacokinetics Service-Hemophilia (WAPPS-Hemo): A Service for Bayesian Post Hoc Estimation. Journal of Pharmacokinetics and Pharmacodynamics. S47-S47. 2015
- A population approach to hemophilia pharmacokinetics. Wapps: a web-service for bayesian post hoc estimation. Journal of Thrombosis and Haemostasis. 44-45. 2015
- Assessing the indication and success of treatment for haemophilia patients: results from a delphi panel. Journal of Thrombosis and Haemostasis. 558-558. 2015
- Bayesian approach to the assessment of the population specific risk of inhibitors. Journal of Thrombosis and Haemostasis. 357-357. 2015
- Determinants of inhibitor development in previously treated hemophilia A patients. Journal of Thrombosis and Haemostasis. 149-149. 2015
- Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor IX FC fusion protein and other recombinant factor IX products. Journal of Thrombosis and Haemostasis. 324-324. 2015
- Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor VIII FC fusion protein and other recombinant factor VIII products. Journal of Thrombosis and Haemostasis. 324-324. 2015
- Investigating potential determinants of ITI success using immune gene expression profiling: a preliminary study. Journal of Thrombosis and Haemostasis. 567-567. 2015
- OPTIMAL DURATION OF ANTICOAGULANT THERAPY FOR THE TREATMENT OF CANCER-ASSOCIATED THROMBOSIS. Haematologica. 20-20. 2015
- Pharmacokinetic characteristics of factor VIII and IX concentrates - a systematic review. Journal of Thrombosis and Haemostasis. 357-358. 2015
- Surveillance study of safety and efficacy of a VWF/FVIII concentrate in patients with von willebrand disease (WIL-20) - a planned interim analysis. Journal of Thrombosis and Haemostasis. 503-503. 2015
- Utilization of anti-inhibitors products and inhibitors status of severe hemophilia patients: 5 years national data from the Canadian hemophilia assessment and resource management system. Journal of Thrombosis and Haemostasis. 362-362. 2015
- Population pharmacokinetics for busy clinicians and active patients: how to get the most out of it?. Haemophilia. 13-13. 2015
- A Systematic Review of Definitions and Reporting of Bleeding Outcome Measures in Hemophilia. Blood. 2821-2821. 2014
- Investigating determinants of inhbitor development to factor VIII molecules in previously treated hemophilia A patients. Journal of Thrombosis and Haemostasis. 65-65. 2014
- Risk of inhibitor development in previously treated patients with positive inhibitor history or low titer of inhibitor at baseline: results of a survey of hemophilia experts. Journal of Thrombosis and Haemostasis. 34-34. 2014
- An evaluation of whether the ankle is now the dominant site of chronic hemophilic arthropathy in young adults with severe hemophilia. Haemophilia. 73-73. 2014
- An indirect comparison of the efficacy of prophylactic use of rFIXFc and other rFIX products and simulation of the effect of compliance on effectiveness. Haemophilia. 117-118. 2014
- An indirect comparison of the efficacy of prophylactic use of rFVIIIFc and other rFVIII products and model of the effect of compliance. Haemophilia. 119-119. 2014
- Assessment of patient preferences and perceived value of the comprehensive interdisciplinary combined hemophilia and orthopedic clinic using a validated questionnaire. Haemophilia. 146-146. 2014
- Cardiac risk factors in older patients with hemophilia: Report of the age related cardiovascular disease in hemophilia epidemiologic research (archer) study. Haemophilia. 5-5. 2014
- Factor VII deficiency patients: 5 years factors concentrates utilization trend based on the Canadian Hemophilia Assessment and Resource Management System (CHARMS). Haemophilia. 105-105. 2014
- Factors influencing quality of life in Chinese adults with hemophilia: Results from the HERO study. Haemophilia. 170-170. 2014
- Fathers' and Mothers' Perceptions and Communication on Carrier Status and Diagnosis of Congenital Haemophilia: Global Results from the Haemophilia Experiences, Results and Opportunities (HERO) Study. Haemophilia. 164-164. 2014
- Investigating Attitudes and Practices of Canadian Physiotherapists on Sexual Health: A Comparison to the HERO Dataset. Haemophilia. 153-154. 2014
- Physiotherapy and point of care ultrasonography in the management of hemophilia: Training phase. Haemophilia. 154-154. 2014
- Safety of antihemophilic factor recombinant plasma/albumin-free method [rAHF-PFM] in hemophilia A patients with low titer inhibitors or a personal history of inhibitor: A meta-analysis of ADVATE Post-Authorization Safety Studies data. Haemophilia. 46-46. 2014
- Does product type influence the development on inhibitor in PTPs and PUPs?. Haemophilia. 88-88. 2014
- Does product type influence the development on inhibitor in PTPs and PUPs?. Haemophilia. 6-6. 2014
- Investigating determinants of inhbitor development to factor VIII molecules in previously treated hemophilia A patients. Haemophilia. 38-38. 2014
- The use of FVIII concentrate in hemophilia A patients with low titer inhibitors or a personal history of inhibitor: a meta-analysis of advate post-authorization safety studies in different countries. Haemophilia. 42-42. 2014
- Venous thromboembolism prophylaxis in elderly patients admitted to Italian internal medicine wards. Journal of Thrombosis and Haemostasis. 80-81. 2013
- Developing a Two-Sided Intervention To Facilitate Shared Decision Making In Haemophilia: Decision Boxes For Clinicians and Brief Patient Decision Aids For Patients. Blood. 2013
- Association between treatment regimen and quality of life assessed by EQ-5D-3L and pain interference in adults with haemophilia with and without inhibitors in the HERO study. Journal of Thrombosis and Haemostasis. 1068-1068. 2013
- Association of treatment regimen and location with bleed frequency, quality of life and comorbidities in adults and children with haemophilia from the HERO study. Journal of Thrombosis and Haemostasis. 1067-1068. 2013
- Defective indoleamine 2,3-dioxygenase induction is associated with inhibitor development in severe hemophilia A patients carrying F8 gene null mutations. Journal of Thrombosis and Haemostasis. 34-34. 2013
- Do bleed rates and haemophilia treatment centre/provider utilisation vary with physical activity risk in adults with haemophilia: An analysis from the HERO study. Journal of Thrombosis and Haemostasis. 1067-1067. 2013
- Do inhibitors, treatment regimen and bleed frequency impact haemophilia treatment centre and provider utilisation: an analysis of adults with haemophilia in the HERO study. Journal of Thrombosis and Haemostasis. 798-799. 2013
- Do inhibitors, treatment regimen and bleed frequency impact parent-directed haemophilia treatment centre and provider utilisation: An analysis of parents of children with haemophilia in the HERO study. Journal of Thrombosis and Haemostasis. 1064-1064. 2013
- Does higher risk activity change bleed frequency and haemophilia treatment center/provider utilisation in children with haemophilia: an analysis from the HERO study. Journal of Thrombosis and Haemostasis. 1066-1067. 2013
- Effect of type and intensity of FVIII exposure on inhibitors development in hemophilia A: first results of an individual patient data meta-analytic project. Journal of Thrombosis and Haemostasis. 33-34. 2013
- External validation and updating of the Vienna Prediction Model for recurrent venous thromboembolism using a pooled individual patient data database. Journal of Thrombosis and Haemostasis. 879-880. 2013
- Meta-analysis of Post Authorization Safety Studies: worldwide postmarking surveillance of hemophilia A patients treated with antihemophilic factor recombinant plasma/albumin-free method rAHF-PFM. Journal of Thrombosis and Haemostasis. 1075-1076. 2013
- Potential relationships between negative impacts on employment or relationships and haemophilia treatment centre/provider utilisation: an analysis of adults with haemophilia from the HERO study. Journal of Thrombosis and Haemostasis. 1065-1065. 2013
- Potential relationships between negative impacts on employment or relationships with haemophilia centre/provider utilisation: An analysis of parents of children with haemophilia from the HERO study. Journal of Thrombosis and Haemostasis. 1064-1065. 2013
- Quality of life and well-being of haemophilia patients and parents in China: subgroup analysis of the HERO study. Journal of Thrombosis and Haemostasis. 1083-1083. 2013
- Relationship of quality of life, pain and self-reported arthritis with activity, bleed rate and haemophilia treatment centre/provider utilisation: results from the HERO study. Journal of Thrombosis and Haemostasis. 1065-1066. 2013
- Access to haemophilia treatment centres (HTCS), treatment and information sources: european results from the hero study. Haemophilia. 35-36. 2013
- Demographic characteristics of European respondents in the hero study. Haemophilia. 27-27. 2013
- Effect of turoctocog alfa on quality of life of children, adolescents and adults with haemophilia A: results from two clinical trials. Haemophilia. 23-23. 2013
- Effects of haemophilia on relationships, intimacy and family: european results from the hero study. Haemophilia. 27-28. 2013
- Quality of life in adults with haemophilia: european results from the hero study. Haemophilia. 34-35. 2013
- Hemophilia Experiences, Results and Opportunities (HERO) Study: US Respondent Demographics and Impact of Diagnosis On Career and Lifestyle Decisions and Quality of Life. Blood. 4244-4244. 2012
- Assessment of treatment-related risk factors for inhibitor development in previously untreated hemophilia A patients: Different statistical approaches. Haemophilia. 86-87. 2012
- Clinical presentation and management of adult patients responding to the Hemophilia Experiences Results Opportunities (HERO) study. Haemophilia. 14-14. 2012
- Clinical presentation and management of pediatric hemophilia patients as reported by parents surveyed in the Haemophilia Experiences Results Opportunities (HERO) survey. Haemophilia. 17-17. 2012
- Demographic characteristics of adult patient respondents in the Hemophilia Experiences Results Opportunities (HERO) study. Haemophilia. 169-169. 2012
- Demographic characteristics of parents of children/adolescents with hemophilia responding in the Hemophilia Experiences Results Opportunities (HERO) study. Haemophilia. 169-169. 2012
- Hemophilia knowledge and frequently used and valued information sources: Patient/parent perceptions from the Hero study. Haemophilia. 54-54. 2012
- Impact of hemophilia on interpersonal relationships: Assessment of parent/caregiver respondents in the hemophilia experiences, results, opportunities (hero) study. Haemophilia. 63-63. 2012
- Impact of hemophilia on relationships with partners, family, and friends: Assessment of adult patient respondents in the hemophilia experiences, results, opportunities (HERO) study. Haemophilia. 63-63. 2012
- Low bone mineral density and increased fat mass in boys with severe hemophilia. Haemophilia. 23-23. 2012
- Nutritional intake and bone mineral density in boys with severe hemophilia. Haemophilia. 23-23. 2012
- Osteochondral Lesions of the Ankle Joint in Patients with Hemophilia A: A Retrospective Case Series. Haemophilia. 128-128. 2012
- Predictors of success of immune tolerance induction in hemophilia A patients with high-responding inhibitors: A score from the Italian registry. Haemophilia. 85-85. 2012
- Qualitative and quantitative assessment of sexual intimacy in adult patients in the hemophilia experiences results opportunities (HERO) study. Haemophilia. 143-143. 2012
- Quality of life (QOL) and well-being of hemophilia patients and parents managing hemophilia: Hero study analysis. Haemophilia. 177-177. 2012
- Concentrate type and dose in hemophilia A patients: is there an independent effect on risk of inhibitor formation?. Haemophilia. 11-11. 2012
- The use of the clinical trial design in Hemophilia: methodological considerations. Haemophilia. 8-8. 2012
- Indoleamine 2,3-Dioxygenase and Peripheral Tolerance to Exogenous Factor VIII: A Multi-Centre Pilot Study. Blood. 16-16. 2011
- Predicting Disease Recurrence in Patients with Previous Unprovoked Venous Thromboembolism: The DASH Prediction Score. Blood. 251-252. 2011
- Bioequivalence of B-domain deleted and plasma derived FVIII concentrates. Journal of Thrombosis and Haemostasis. 682-682. 2011
- HERO - an international initiative exploring unmet psychosocial needs in haemophilia: results from a qualitative survey targeting 150 subjects in seven countries. Journal of Thrombosis and Haemostasis. 675-675. 2011
- HERO, an international initiative exploring unmet psychosocial needs in haemophilia: characteristics of a quantitative survey targeting 1200 subjects in 12 countries. Journal of Thrombosis and Haemostasis. 674-675. 2011
- Heterogeneity of the clinical, laboratory and molecular markers of VWD type 3: results from the retrospective/prospective studies on 122/52 Italian patients. Journal of Thrombosis and Haemostasis. 453-453. 2011
- Impact of persistent antiphospholipid antibodies on symptomatic thromboembolism in children: a systematic review & meta-analysis [observational studies]. Journal of Thrombosis and Haemostasis. 514-514. 2011
- Psychosocial aspects of living with haemophilia: the hero project and a narrative review of the published literature. Journal of Thrombosis and Haemostasis. 675-675. 2011
- Predictive model to assess the risk of inhibitor development in children with severe and moderate haemophilia A - results of a multicenter cohort study. Haemophilia. 361-362. 2011
- Predictors of inhibitor development in haemophilia A previously untreated patients: the role of factor concentrate type. An individual patient data meta-analysis. Haemophilia. 361-361. 2011
- A Predictive Model for the Development of High-Responding Inhibitor In Children. with Severe and Moderate Hemophilia A- Results of a Multicenter Cohort Study. Blood. 313-313. 2010
- Clinical Efficacy and Safety Versus Biological Response of Desmopressin (DDAVP) In Inherited Von Willebrand Disease (VWD) Types 1 and 2: Initial Results From the International Study Group on DDAVP In VWD In a Cohort of 229 Patients. Blood. 110-111. 2010
- Impact of Persistent Antiphospholipid Antibodies on Symptomatic Thromboembolism In Children: A Systematic Review & Meta-Analysis [Observational Studies]. Blood. 1303-1303. 2010
- Bioequivalence of B-domain deleted and plasma derived FVIII concentrates. Haemophilia. 38-38. 2010
- Bone mineral density in hemophilia patients: a meta-analysis. Haemophilia. 98-98. 2010
- Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Haemophilia. 126-126. 2010
- Effect of plasma-derived or recombinant factor VIII on inhibitor development: a systematic review. Haemophilia. 74-74. 2010
- Predictors of success in immune tolerance induction (ITI) in haemophilia A patients with high-responding inhibitors: the Italian ITI registry. Haemophilia. 71-71. 2010
- Recombinant factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Haemophilia. 24-24. 2010
- IDIOPATHIC VEIN THROMBOSIS: IDENTIFICATION OF POPULATIONS AT DIFFERENT RISK OF RELAPSE FOLLOWING ORAL ANTICOAGULANT TREATMENT. THE RESULTS OF THE 'EXTENDED-DACUS STUDY'. Haematologica. 218-218. 2010
- PREVALENCE AND DETERMINANTS OF BLEEDING IN SEVERE VON WILLEBRAND DISEASE TYPE 3: RESULTS OF RETRO/PROSPECTIVE STUDIES IN A COHORT OF 105/52 ITALIAN PATIENTS. Haematologica. 217-217. 2010
- IDIOPATHIC VEIN THROMBOSIS: IDENTIFICATION OF POPULATIONS AT DIFFERENT RISK OF RELAPSE FOLLOWING ORAL ANTICOAGULANT TREATMENT. THE RESULTS OF THE 'EXTENDED-DACUS STUDY'. Haematologica. 218-218. 2010
- PREVALENCE AND DETERMINANTS OF BLEEDING IN SEVERE VON WILLEBRAND DISEASE TYPE 3: RESULTS OF RETRO/PROSPECTIVE STUDIES IN A COHORT OF 105/52 ITALIAN PATIENTS. Haematologica. 217-217. 2010
- Effect of plasma-derived or recombinant factor VIII on inhibitor development. A systematic review. Haemophilia. 410-410. 2010
- Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies. Blood. 1534-1535. 2009
- Prevalence and Determinants of Bleeding in Severe Von Willebrand Disease Type 3: Results of Retro/Prospective Studies in a Cohort of 105/52 Italian Patients.. Blood. 1356-1357. 2009
- Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature. Blood. 1224-1225. 2009
- Audit of the clinical use of fresh-frozen plasma in umbria: study design and results. Journal of Thrombosis and Haemostasis. 860-860. 2009
- Bone mineral density in hemophilia patients: a meta-analysis. Journal of Thrombosis and Haemostasis. 806-806. 2009
- Central nervous system (CNS) bleeding in patients with rare bleeding disorders (RBDS). Journal of Thrombosis and Haemostasis. 42-43. 2009
- Clinical prediction guide to predict thrombosis recurrence after a first unprovoked venous thromboembolism. Journal of Thrombosis and Haemostasis. 266-266. 2009
- Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the two coagulation disorders. Journal of Thrombosis and Haemostasis. 503-503. 2009
- Computer assisted VKA monitoring with point of care device by general practitioners. Journal of Thrombosis and Haemostasis. 473-473. 2009
- D-dimer to predict thrombosis recurrence after unprovoked venous thromboembolism: effect of patient- and D-dimer-related factors on recurrence prediction. Journal of Thrombosis and Haemostasis. 265-265. 2009
- D-dimer to predict thrombosis recurrence: comparison of aggregate data and individual patient data meta-analyses. Journal of Thrombosis and Haemostasis. 1069-1069. 2009
- Does patient sex and prior hormonal therapy predict risk for thrombosis recurrence after a first venous thromboembolism?. Journal of Thrombosis and Haemostasis. 79-79. 2009
- Does the clinical presentation of venous thromboembolism predict the risk for and type of thrombosis recurrence?. Journal of Thrombosis and Haemostasis. 723-724. 2009
- Factor VIII gene (F8) mutations as a predictor of outcome in immune tolerance induction (ITI) in hemophilia A patients with high-responding inhibitors. Journal of Thrombosis and Haemostasis. 191-192. 2009
- Intracranial haemorrhage in haemophilia A and B: an italian retrospective survey. Journal of Thrombosis and Haemostasis. 42-42. 2009
- Multicentric evaluation of current dosing practice of recombinant fix in italy. Journal of Thrombosis and Haemostasis. 1153-1153. 2009
- Plasma derived (PD) and recombinant (R) factor VIII (FVIII) concentrates induce a different rate of inhibitor development in hemophilia A patients. a systematic review of the literature. Journal of Thrombosis and Haemostasis. 115-115. 2009
- Prospective assessment of clinical endpoints of VKA treatment in a primary care computer assisted management model. Journal of Thrombosis and Haemostasis. 473-473. 2009
- Venous thromboembolism recurrence after a first episode of provoked venous thrombosis due to a transient risk factor. A systematic review of the literature. Journal of Thrombosis and Haemostasis. 413-413. 2009
- International clinical trials are the best way to improve global haemophilia care? No. Haemophilia. 625-625. 2009
- Venous Thromboembolism Recurrence after a First Episode of Provoked Venous Thrombosis Due to a Transient Risk Factor. A Systematic Review of the Literature. Blood. 1042-1042. 2008
- Antiviral therapy for chronic hepatitis C in haemophilia patients with human immunodeficiency virus. Cochrane Database of Systematic Reviews. 39-39. 2008
- Causes of death among Italian hemophiliacs: results from the Italian Association of Hemophilia Centers (AICE) Survey. Haemophilia. 141-141. 2008
- Clinical audit of fresh frozen plasma usage in Umbria, Italy. Haemophilia. 86-86. 2008
- Critical appraisal of five international guidelines on fresh frozen plasma clinical use. Haemophilia. 89-89. 2008
- Factor IX pharmacokinetics: differences between plasma‐derived and recombinant products and the clinical and economic implications: a meeting report. Haemophilia. 873-875. 2008
- Haemophilia A and B and other rare bleeding disorders: an Italian retrospective survey on the intracranial haemorrhagic episodes. Haemophilia. 32-32. 2008
- Immune tolerance induction (ITI) in patients with hemophilia A and inhibitors: the Italian retrospective-prospective registry - the PROFIT study. Haemophilia. 57-57. 2008
- Inhibitor development in mild/moderate haemophilia: could influenza vaccination have been the trigger?. Haemophilia. 45-45. 2008
- Pharmacokinetics of reformulated B-domain deleted recombinant factor VIII (BDD-rFVIII) concentrate using chromogenic and one-stage assays with pooled normal plasma (PNP) and refacto laboratory standard (RLS). Haemophilia. 10-10. 2008
- Replacement therapy with recombinant FIX - multicentre evaluation of current dosing practice in Italy. Haemophilia. 13-13. 2008
- The haemophilia registry of the Italian Association of Haemophilia Centres. Haemophilia. 30-31. 2008
- Pharmacokinetics of the reformulated B-DOMAIN deleted recombinant factor VIII (BDD-RFVIII) concentrate using chromogenic and one-stage assays with pooled normal plasma (PNP) and refacto laboratory standard (RLS). Haematologica. 131-132. 2007
- Pharmacokinetics of the reformulated B-domain deleted recombinant factor VIII concentrate using chromogenicand one-stage assays with pooled normal plasma and refacto laboratory standard. Haematologica. 33-33. 2007
- Systematic Review of Randomized Controlled Trials of Prophylactic Clotting Factor Concentrate in Hemophilia.. Blood. 3114-3114. 2005
- Accreditation standard for surveillance center for patients undergoing oral anticoagulant therapy. Rivista di Medicina di Laboratorio. 52-56. 2002
- Low molecular weight heparin for prevention of venous thromboembolism in elective neurosurgery: A metanalysis. Thrombosis and Haemostasis. 652-652. 1999
- Plasma homocysteine measurement: Comparison of three different assay methods in plasma from vascular patients. Thrombosis and Haemostasis. 772-773. 1999
- Risk factors for venous thromboembolism in patients undergoing elective neurosurgery. Thrombosis and Haemostasis. 6-6. 1999
- Serine base exchange enzyme in commercially available porcine lyophilized platelets: Different effect of unfractionated heparin and low molecular weight heparin. Thrombosis and Haemostasis. 675-676. 1999
- The role of thrombophilic states in the bleeding tendency of patients with hemophilia. Thrombosis and Haemostasis. 489-489. 1999
- Three-months compared with one-year of oral anticoagulant treatment after a first idiopathic deep vein thrombosis: The warfarin optimal duration Italian trial (WODIT). Thrombosis and Haemostasis. 684-685. 1999
- Enoxaparin plus compression stockings versus compression stockings alone in the prevention of venous thromboembolism (VTE) in neurosurgery patients: A randomised double blind venography study. Thrombosis and Haemostasis. O1576-O1576. 1997
- Plasma heparin level and coronary patency in patients with acute myocardial infarction treated with a double rt-PA bolus and randomised to two different heparin regimens. Thrombosis and Haemostasis. P2050-P2050. 1997
- Withdrawal of warfarin therapy after deep vein thrombosis: A randomised study on the effects of a very low fixed dose regimen. Thrombosis and Haemostasis. PS335-PS335. 1997
- EFFECTS OF DERMATAN SULFATE ON ACTIVATED PARTIAL THROMBOPLASTIN TIME DETERMINED WITH 5 DIFFERENT REAGENTS. Thrombosis and Haemostasis. 1353-1353. 1995
- FIBRINOGENOLYSIS AND THROMBIN ACTIVATION AFTER ACCELERATED WEIGHT-ADJUSTED OR CONVENTIONAL ADMINISTRATION OF RT-PA FOR PULMONARY-EMBOLISM. Thrombosis and Haemostasis. 1329-1329. 1995
- POSTDISCHARGE CLINICALLY OVERT THROMBOEMBOLIC EVENTS IN ORTHOPEDIC-SURGERY PATIENTS WITH NEGATIVE VENOGRAPHY. Thrombosis and Haemostasis. 1095-1095. 1995
- THE DISPLACEMENT OF NONSPECIFICALLY BOUND UNFRACTIONATED HEPARIN FROM PLASMA-PROTEINS PRODUCES AN ANTITHROMBOTIC EFFECT. Thrombosis and Haemostasis. 963-963. 1995
- EX-VIVO COMPARISON OF THE NONSPECIFIC-BINDING OF UNFRACTIONATED HEPARIN AND ENOXAPARIN TO PLASMA-PROTEINS. Thrombosis and Haemostasis. 857-857. 1993
- INHIBITION OF FLUID-PHASE AND CLOT-BOUND THROMBIN - EFFECTS OF HEPARIN, HIRUDIN AND A THROMBIN-INHIBITING DECAPEPTIDE (LU-58463). Thrombosis and Haemostasis. 1301-1301. 1993
- KINETICS OF PLASMA THROMBIN NEUTRALIZING ACTIVITY IN PATIENTS WITH DEEP-VEIN THROMBOSIS TREATED WITH SUBCUTANEOUS HEPARIN TWICE A DAY. Thrombosis and Haemostasis. 857-857. 1993
- PLASMA HALF-LIFE OF THE ANTI-IIA ACTIVITY OF LOW-MOLECULAR-WEIGHT HEPARINS ASSESSED WITH A SENSITIVE TEST (PTNA). Thrombosis and Haemostasis. 768-768. 1993
- PLATELET INHIBITION INDUCED BY PLASMINOGEN ACTIVATORS - ROLE OF FIBRINOGEN DEGRADATION PRODUCTS. Thrombosis and Haemostasis. 1337-1337. 1993
journal articles
- Attitudes and perceptions of medical researchers towards the use of artificial intelligence chatbots in the scientific process: an international cross-sectional survey.. The Lancet Digital Health. S2589-7500(24)00202-4. 2024
- A mixed-methods survey and focus group study to understand researcher and clinician preferences for a Journal transparency Tool.. Scientific Reports. 14:26626. 2024
- Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.. New England Journal of Medicine. 391:1108-1118. 2024
- Thrombophilia testing: does practice follow guidelines?. Blood Advances. 8:4948-4949. 2024
- Boosting efficiency in a clinical literature surveillance system with LightGBM.. PLOS Digital Health. 3:e0000299. 2024
- The McMaster Health Information Research Unit: Over a Quarter-Century of Health Informatics Supporting Evidence-Based Medicine. Journal of Medical Internet Research. 26:e58764-e58764. 2024
- Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans. AAPS PharmSciTech. 26:81. 2024
- Development of a Plasminogen Population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS‐Hemo platform. Haemophilia. 30:988-997. 2024
- Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi‐country severe WAPPS‐Hemo haemophilia patients. Haemophilia. 30:925-932. 2024
- Prothrombin complex concentrate for emergency surgery in patients on oral Xa-inhibitors. Journal of Thrombosis and Haemostasis. 22:2761-2766. 2024
- GRADE concept paper 8: judging the certainty of discrimination performance estimates of prognostic models in a body of validation studies. Journal of Clinical Epidemiology. 170:111344-111344. 2024
- Hemostatic management of von Willebrand disease during childbirth with a plasma-derived von Willebrand factor/factor VIII concentrate. Journal of Thrombosis and Haemostasis. 22:2739-2744. 2024
- Scoping review of the recommendations and guidance for improving the quality of rare disease registries. Orphanet Journal of Rare Diseases. 19:187. 2024
- Health utilities in adults with hemophilia A: A retrospective cohort study. Haemophilia. 30:733-742. 2024
- Protocol for the development of the Chatbot Assessment Reporting Tool (CHART) for clinical advice. BMJ Open. 14:e081155-e081155. 2024
- What You May Have Missed in 2023: Keeping Up With the Constant Flow of New Medical Evidence. ACP journal club. 177:S1-S2. 2024
- Lower-dose emicizumab prophylaxis: can less be more?. Journal of Thrombosis and Haemostasis. 22:922-925. 2024
- Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada. Haemophilia. 30:345-354. 2024
- GRADE Concept 7: Issues and Insights Linking Guideline Recommendations to Trustworthy Essential Medicine Lists. Journal of Clinical Epidemiology. 166:111241-111241. 2024
- American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Advances. 7:7101-7138. 2023
- Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada. Research and Practice in Thrombosis and Haemostasis. 7:102265-102265. 2023
- The World Federation of Hemophilia World Bleeding Disorders Registry: insights from the first 10,000 patients. Research and Practice in Thrombosis and Haemostasis. 7:102264-102264. 2023
- Impact of strategies to mitigate misinformation in diverse settings and populations: a protocol for a living evidence synthesis. BMJ Open. 13:e076672-e076672. 2023
- Inhibitors in hemophilia: association with surgery plans and outcomes in a retrospective cohort study. Research and Practice in Thrombosis and Haemostasis. 7:102228-102228. 2023
- OC 06.5 Use of Emicizumab for the Treatment of Acquired Hemophilia A: A Systematic Review. Research and Practice in Thrombosis and Haemostasis. 7:100462. 2023
- OC 20.5 The WFH Gene Therapy Registry: A Collaborative Approach Towards a Global Resource for the Long-Term Follow-up of People with Hemophilia Treated with Gene Therapy. Research and Practice in Thrombosis and Haemostasis. 7:100445. 2023
- OC 24.1 Effect of the Type of F9 Mutation on the Pharmacokinetic Profile of Patients with Hemophilia B Treated with Extended Half-Life FIX Concentrates. Research and Practice in Thrombosis and Haemostasis. 7:100443. 2023
- OC 24.2 Estimated Factor VIII Activity Levels at the Time of Bleeding Events in Individuals with Hemophilia a Without Inhibitors. Research and Practice in Thrombosis and Haemostasis. 7:100436. 2023
- OC 24.4 Effect of F8 Mutations and Von Willebrand Factor on Pharmacokinetics of FVIII Concentrates in Severe Hemophilia A. Research and Practice in Thrombosis and Haemostasis. 7:100438. 2023
- PB0175 Impact of Reagent on the Estimation of Eloctate and Adynovate Pharmacokinetic (PK) Parameters?. Research and Practice in Thrombosis and Haemostasis. 7:101061. 2023
- PB0191 myGTR: A Patient Engagement Tool from the World Federation of Hemophilia Gene Therapy Registry. Research and Practice in Thrombosis and Haemostasis. 7:101212. 2023
- PB0644 Evaluation of the Burden of Bone Fractures in People Living with Hemophilia: A Registry-Based Case-Control Study. Research and Practice in Thrombosis and Haemostasis. 7:101184. 2023
- PB0661 Real-World Effectiveness and Safety of Damoctocog Alfa Pegol in Canadian Patients with Hemophilia A: Interim Results from the HEM-POWR Study. Research and Practice in Thrombosis and Haemostasis. 7:101178. 2023
- PB0827 WFH World Bleeding Disorders Registry Launches the First Global Data Collection on People with von Willebrand Disease. Research and Practice in Thrombosis and Haemostasis. 7:101579. 2023
- PB0837 Analysis of the Change in Diagnosis of von Willebrand Disease by Region and Economic Status. Research and Practice in Thrombosis and Haemostasis. 7:101562. 2023
- PB1392 Late Diagnosis of Two Adult Siblings with Bernard Soulier Syndrome (BSS). Research and Practice in Thrombosis and Haemostasis. 7:101516. 2023
- Protocol for a living evidence synthesis on variants of concern and COVID-19 vaccine effectiveness. Vaccine. 41:6411-6418. 2023
- Bleeding events in people with congenital haemophilia A without factor VIII inhibitors receiving prophylactic factor VIII treatment: A systematic literature review. Haemophilia. 29:954-962. 2023
- Reported prevalence of von Willebrand disease worldwide in relation to income classification. Haemophilia. 29:975-986. 2023
- Von Willebrand Disease: Gaining a global perspective. Haemophilia. 29:1104-1112. 2023
- Deep learning to refine the identification of high-quality clinical research articles from the biomedical literature: Performance evaluation. Journal of Biomedical Informatics. 142:104384-104384. 2023
- GRADE guidance 36: updates to GRADE's approach to addressing inconsistency. Journal of Clinical Epidemiology. 158:70-83. 2023
- Good or best practice statements: proposal for the operationalisation and implementation of GRADE guidance. BMJ Evidence-Based Medicine. 28:189-196. 2023
- The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A. Blood. 141:1147-1158. 2023
- Cost‐utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada. Haemophilia. 29:488-497. 2023
- Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes. Research and Practice in Thrombosis and Haemostasis. 7:100106-100106. 2023
- Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: A scoping review. Research and Practice in Thrombosis and Haemostasis. 7:100007-100007. 2023
- Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature. Haemophilia. 29:33-44. 2023
- Recommendations and guidelines for creating scholarly biomedical journals: A scoping review. PLoS ONE. 18:e0282168-e0282168. 2023
- Development and internal validation of a clinical prediction model for the diagnosis of immune thrombocytopenia. Journal of Thrombosis and Haemostasis. 20:2988-2997. 2022
- Which actionable statements qualify as good practice statements In Covid-19 guidelines? A systematic appraisal. BMJ Evidence-Based Medicine. 27:361-369. 2022
- Switching from standard to extended half‐life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics. Haemophilia. 28:e237-e244. 2022
- GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. Journal of Clinical Epidemiology. 150:216-224. 2022
- GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions. Journal of Clinical Epidemiology. 150:225-242. 2022
- Overall prognosis of preschool autism spectrum disorder diagnoses. Clinical Respiratory Journal. 2022:CD012749. 2022
- A personalized limited sampling approach to better estimate terminal half‐life of FVIII concentrates. Journal of Thrombosis and Haemostasis. 20:2012-2021. 2022
- A multistakeholder development process to prioritize and translate COVID-19 health recommendations for patients, caregivers and the public. A case study of the COVID-19 recommendation map. Journal of Clinical Epidemiology. 148:104-114. 2022
- An evaluation of the COVID-19 recommendation map identified diverging clinical and public health guidance. Journal of Clinical Epidemiology. 147:83-94. 2022
- EE476 Cost-Effectiveness of Emicizumab Prophylaxis in Patients with Hemophilia a without Inhibitors. Value in Health. 25:S428-S428. 2022
- von Willebrand factor propeptide variants lead to impaired storage and ER retention in patient‐derived endothelial colony‐forming cells. Journal of Thrombosis and Haemostasis. 20:1599-1609. 2022
- Risk factors for bleeding in people living with hemophilia A and B treated with regular prophylaxis: A systematic review of the literature. Journal of Thrombosis and Haemostasis. 20:1364-1375. 2022
- Emicizumab state‐of‐the‐art update. Haemophilia. 28:103-110. 2022
- Extended reporting guidance for vaccine effectiveness studies for variants of concern for COVID-19. Vaccine. 40:2986-2987. 2022
- Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia. HemaSphere. 6:e694-e694. 2022
- User-Centered Development and Testing of the Online Patient-Reported Outcomes, Burdens, and Experiences (PROBE) Survey and the myPROBE App and Integration With the Canadian Bleeding Disorder Registry: Mixed Methods Study. JMIR Human Factors. 9:e30797-e30797. 2022
- GRADE concept paper 2: Concepts for judging certainty on the calibration of prognostic models in a body of validation studies. Journal of Clinical Epidemiology. 143:202-211. 2022
- New methods facilitated the process of prioritizing questions and health outcomes in guideline development. Journal of Clinical Epidemiology. 143:91-104. 2022
- Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study. Research and Practice in Thrombosis and Haemostasis. 6:e12661-e12661. 2022
- Utilization of a surgical database to provide care and assess perioperative treatment and outcomes in patients with bleeding disorders. European Journal of Haematology. 108:232-243. 2022
- Accuracy and Acceptability of Wrist-Wearable Activity-Tracking Devices: Systematic Review of the Literature. Journal of Medical Internet Research. 24:e30791-e30791. 2022
- A taxonomy and framework for identifying and developing actionable statements in guidelines suggests avoiding informal recommendations. Journal of Clinical Epidemiology. 141:161-171. 2022
- POSC37 Economic Cost of Treatment in Canada: A Multi-Centre, Retrospective Study. Value in Health. 25:S93-S93. 2022
- Sexual issues in people with haemophilia: Awareness and strategies for overcoming communication barriers. Haemophilia. 28:36-41. 2022
- Knowledge translation strategies for sharing evidence-based health information with older adults and their caregivers: findings from a persona-scenario method. BMC Geriatrics. 21:665. 2021
- A Deep Learning Approach to Refine the Identification of High-Quality Clinical Research Articles From the Biomedical Literature: Protocol for Algorithm Development and Validation. JMIR Research Protocols. 10:e29398-e29398. 2021
- How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines. Blood Advances. 5:4721-4726. 2021
- Evaluation of the sexual health in people living with hemophilia. Haemophilia. 27:993-1001. 2021
- Development and application of health outcome descriptors facilitated decision-making in the production of practice guidelines. Journal of Clinical Epidemiology. 138:115-127. 2021
- External qualification of the Web‐Accessible Population Pharmacokinetic Service–Hemophilia (WAPPS‐Hemo) models for octocog alfa using real patient data. Research and Practice in Thrombosis and Haemostasis. 5:e12599-e12599. 2021
- The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B. Research and Practice in Thrombosis and Haemostasis. 5:e12601-e12601. 2021
- Machine Learning Approaches to Retrieve High-Quality, Clinically Relevant Evidence From the Biomedical Literature: Systematic Review. JMIR Medical Informatics. 9:e30401-e30401. 2021
- Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time. Haemophilia. 27:e596-e608. 2021
- Factor product utilization and health outcomes in patients with haemophilia A and B on extended half‐life concentrates: A Canadian observational study of real‐world outcomes. Haemophilia. 27:751-759. 2021
- Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B. Clinical Respiratory Journal. 2021:CD014201. 2021
- Recommended primary outcomes for clinical trials evaluating hemostatic blood products and agents in patients with bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus Conference. Journal of Trauma and Acute Care Surgery. 91:S19-S25. 2021
- Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. Journal of Thrombosis and Haemostasis. 19:1896-1906. 2021
- Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia. Haemophilia. 27:e525-e529. 2021
- Comparison of single subject and population‐based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A. Haemophilia. 27:626-633. 2021
- Accuracy and Acceptability of Wrist-Wearable Activity-Tracking Devices: Systematic Review of the Literature (Preprint) 2021
- Methodological considerations for investigating oral anticoagulation persistence in atrial fibrillation. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 7:251-260. 2021
- Patient‐relevant health outcomes for hemophilia care: Development of an international standard outcomes set. Research and Practice in Thrombosis and Haemostasis. 5:e12488-e12488. 2021
- Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study. Haemophilia. 27:358-365. 2021
- Optimizing a literature surveillance strategy to retrieve sound overall prognosis and risk assessment model papers. Journal of the American Medical Informatics Association : JAMIA. 28:766-771. 2021
- Derivation of a Pharmacokinetic Model to Include a Plasma-Derived, von Willebrand Factor-Containing Factor VIII (Koate^®-DVI) Concentrate and its Low-Dose Use. Clinical Medicine Insights: Blood Disorders. 15. 2021
- GRADE Concept Paper 1: Validating the “F.A.C.E” instrument using stakeholder perceptions of feasibility, acceptability, cost, and equity in guideline implement. Journal of Clinical Epidemiology. 131:133-140. 2021
- Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia. 27:211-220. 2021
- Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products. Research and Practice in Thrombosis and Haemostasis. 5:349-355. 2021
- Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000–18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. The Lancet Respiratory Medicine. 9:33-42. 2021
- Interventions to Influence Opioid Prescribing Practices for Chronic Noncancer Pain: A Systematic Review and Meta-Analysis. American Journal of Preventive Medicine. 60:e15-e26. 2021
- Non‐severe haemophilia: Is it benign? – Insights from the PROBE study. Haemophilia. 27:17-24. 2021
- A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients. Thrombosis Research. 196:550-558. 2020
- Obtaining and managing data sets for individual participant data meta-analysis: scoping review and practical guide. BMC Medical Research Methodology. 20:113. 2020
- Protocol for a scoping review of outcomes in clinical studies of interventions for venous thromboembolism in adults. BMJ Open. 10:e040122-e040122. 2020
- Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company. Haemophilia. 26:966-974. 2020
- Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 18:3074-3077. 2020
- Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Annals of Hematology. 99:2689-2698. 2020
- Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews. Blood Advances. 4:4929-4944. 2020
- Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. The Lancet Haematology. 7:e746-e755. 2020
- Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis. 18:2503-2512. 2020
- ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis. 18:2486-2495. 2020
- ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis. 18:2496-2502. 2020
- COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. Journal of Clinical Epidemiology. 123:120-126. 2020
- The World Federation of Hemophilia Annual Global Survey 1999‐2018. Haemophilia. 26:591-600. 2020
- World Federation of Hemophilia Gene Therapy Registry. Haemophilia. 26:563-564. 2020
- Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment. Blood Advances. 4:2557-2566. 2020
- Context and Approach in Reporting Evaluations of Electronic Health Record–Based Implementation Projects. ACP journal club. 172:S73-S78. 2020
- Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. Blood Advances. 4:2351-2365. 2020
- Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. Blood. 135:1788-1810. 2020
- Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS‐Hemo project. Haemophilia. 26:384-400. 2020
- Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach. Clinical Pharmacokinetics. 59:605-616. 2020
- GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. Journal of Clinical Epidemiology. 121:62-70. 2020
- Prescriber adherence to guidelines for chronic noncancer pain management with opioids: Systematic review and meta-analysis.. Health Psychology. 39:430-451. 2020
- Translating Clinical Questions by Physicians Into Searchable Queries: Analytical Survey Study. JMIR Medical Education. 6:e16777-e16777. 2020
- Psychological interventions for people with hemophilia. Clinical Respiratory Journal. 2020:CD010215. 2020
- Multicentre pharmacokinetic evaluation of rFVIII‐Fc (efmoroctocog alfa) in a real life and comparison with non‐extended half‐life FVIII concentrates. Haemophilia. 26:282-289. 2020
- Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. Clinical Pharmacokinetics. 59:245-256. 2020
- Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes. Research and Practice in Thrombosis and Haemostasis. 4:326-333. 2020
- Calculation of absolute risk for important outcomes in patients with and without a prognostic factor of interest. Journal of Clinical Epidemiology. 117:46-51. 2020
- Clinical application of Web Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS‐Hemo): Patterns of blood sampling and patient characteristics among clinician users. Haemophilia. 26:56-63. 2020
- Predictors of treatment adherence in patients with chronic disease using the Multidimensional Adherence Model: unique considerations for patients with haemophilia. The Journal of Haemophilia Practice. 7:92-101. 2020
- The eCOVID-19 living recommendations map and gateway to contextualisation. Cochrane Database of Systematic Reviews. 54-57. 2020
- Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dyoxigenase-1 and Heme Oxygenase-1. Frontiers in Immunology. 11:620. 2020
- A comparison of methods for prediction of pharmacokinetics across factor concentrate switching in hemophilia patients. Thrombosis Research. 184:31-37. 2019
- Strategies for eliciting and synthesizing evidence for guidelines in rare diseases. BMC Medical Research Methodology. 19:67. 2019
- Obtaining and managing data sets for individual participant data meta-analysis: scoping review and practical guide 2019
- Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males. ACP journal club. 171:540-540. 2019
- Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients. Journal of Pharmacokinetics and Pharmacodynamics. 46:439-439. 2019
- Corrigendum. Research and Practice in Thrombosis and Haemostasis. 3:771-771. 2019
- Experimental evidences on the role of silica nanoparticles surface morphology on the loading, release and activity of three proteins. Microporous and Mesoporous Materials. 287:220-227. 2019
- A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.. Blood Transfusion. 17:391-398. 2019
- Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Annals of Hematology. 98:2035-2044. 2019
- Home therapy for inherited bleeding disorders in South Africa: Results of a modified Delphi consensus process. SAMJ - South African Medical Journal. 109:639-639. 2019
- [Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A].. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 40:673-677. 2019
- Emicizumab and thrombosis: The story so far. Journal of Thrombosis and Haemostasis. 17:1269-1272. 2019
- Comparative pharmacokinetics of two extended half‐life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?. Journal of Thrombosis and Haemostasis. 17:1085-1096. 2019
- Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. Research and Practice in Thrombosis and Haemostasis. 3:528-541. 2019
- The Development of Clinical Guidelines and Guidance Statements by the Clinical Guidelines Committee of the American College of Physicians: Update of Methods. ACP journal club. 170:863-863. 2019
- Defining certainty of net benefit: a GRADE concept paper. BMJ Open. 9:e027445-e027445. 2019
- The association between platelet transfusions and mortality in patients with critical illness. Transfusion. 59:1962-1970. 2019
- An evidence rating service provided valid correlates of the clinical importance of medical articles and journals. Journal of Clinical Epidemiology. 109:80-89. 2019
- Exploring regional variations in the cross‐cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study. Haemophilia. 25:365-372. 2019
- Screening for Breast Cancer in Average-Risk Women: A Guidance Statement From the American College of Physicians. ACP journal club. 170:547-560. 2019
- Hemophilia trials in the twenty‐first century: Defining patient important outcomes. Research and Practice in Thrombosis and Haemostasis. 3:184-192. 2019
- Impact of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A Patients: A Historically Controlled Observational Study. Thrombosis and Haemostasis. 119:368-376. 2019
- Switching patients in the age of long-acting recombinant products?. Expert Review of Hematology. 12:1-13. 2019
- Joint Bleeding Tendencies in Adult Patients With Hemophilia: It’s Not All Pharmacokinetics. Clinical and Applied Thrombosis/Hemostasis. 25:107602961986205-107602961986205. 2019
- PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies. ACP journal club. 170:51-51. 2019
- Prehospital fresh frozen plasma: Universal life saver or treatment in search of a target population?. Research and Practice in Thrombosis and Haemostasis. 3:12-14. 2019
- Test‐retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains. Haemophilia. 25:75-83. 2019
- Healthcare provider knowledge, attitudes, beliefs, and practices surrounding the prescription of opioids for chronic non-cancer pain in North America: protocol for a mixed-method systematic review. Systematic Reviews. 7:189. 2018
- The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia. Pilot and Feasibility Studies. 4:58. 2018
- The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A. Thrombosis Research. 170:53-59. 2018
- Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age‐matched controls. Haemophilia. 24:726-732. 2018
- Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. BMJ Open. 8:e021900-e021900. 2018
- Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project. Haemophilia. 24:e167-e172. 2018
- Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Research and Practice in Thrombosis and Haemostasis. 2:607-614. 2018
- Haemophilia clinical care and research needs: Assessing priorities. Haemophilia. 24:e270-e273. 2018
- Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Research and Practice in Thrombosis and Haemostasis. 2:535-548. 2018
- Pharmacokinetics and the transition to extended half‐life factor concentrates: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 16:1437-1441. 2018
- A Deep Learning Method to Automatically Identify Reports of Scientifically Rigorous Clinical Research from the Biomedical Literature: Comparative Analytic Study. Journal of Medical Internet Research. 20:e10281-e10281. 2018
- Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes. Haemophilia. 24:60-67. 2018
- Point‐of‐care ultrasonography in haemophilia care: Training and competency for muscular haematomas. Haemophilia. 24:335-337. 2018
- World bleeding disorders registry: The pilot study. Haemophilia. 24:e113-e116. 2018
- Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians.. ACP journal club. 168:569-576. 2018
- Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism. American Journal of Medicine. 131:430-437. 2018
- Guideline on terminology and definitions of updating clinical guidelines: The Updating Glossary. Journal of Clinical Epidemiology. 95:28-33. 2018
- Comorbidities in persons with haemophilia aged 60 years or more compared with age‐matched people from the general population. Haemophilia. 24:e6-e10. 2018
- McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. Journal of Thrombosis and Haemostasis. 16:1656-1664. 2018
- PP93 HTA Role In CoreHEM, A Multi-Stakeholder Core Outcome Set Project. International Journal of Technology Assessment in Health Care. 34:100-101. 2018
- Researching what matters to improve chronic pain care in Canada: A priority-setting partnership process to support patient-oriented research. Canadian Journal of Pain. 2:191-204. 2018
- Systematic reviews do not adequately report or address missing outcome data in their analyses: a methodological survey. Journal of Clinical Epidemiology. 99:14-23. 2018
- Using pharmacokinetics to individualize hemophilia therapy. Hematology. American Society of Hematology. Education Program. 2017:595-604. 2017
- Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 15:2461-2465. 2017
- McMaster Optimal Aging Portal: an evidence-based database for geriatrics-focused health professionals. BMC Research Notes. 10:271. 2017
- Systematic reviews of prognosis studies: a critical appraisal of five core clinical journals. Diagnostic and Prognostic Research. 1:9. 2017
- Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. Thrombosis Research. 160:97-104. 2017
- Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis. Pharmaceutics. 9:47-47. 2017
- Discrimination and Calibration of Clinical Prediction Models. Journal of the American Medical Association (JAMA). 318:1377-1377. 2017
- Minimal dataset for post‐registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 15:1878-1881. 2017
- Point of care ultrasound in haemophilia: Building a strong foundation for clinical implementation. Haemophilia. 23:648-651. 2017
- Overall prognosis of preschool autism spectrum disorder diagnoses. Clinical Respiratory Journal. 2017. 2017
- Computer-Aided Systematic Review Screening Comes of Age. ACP journal club. 167:210-210. 2017
- Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta‐analysis. Blood. 15:1322-1333. 2017
- Exploring some intersections between pharmacokinetics, factor VIII measurement and human morphometrics – impact of recent advances in haemophilia study design on our understanding of optimal haemophilia treatment. Haemophilia. 23:488-490. 2017
- Large scale studies assessing anti‐factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more. British Journal of Haematology. 178:20-31. 2017
- Switching to extended half‐life products in Canada – preliminary data. Haemophilia. 23:e365-e367. 2017
- IDO1 activity in selected immune cells controls antibody responses. Journal of Immunology. 198:67.25-67.25. 2017
- Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products. Haemophilia. 23:408-416. 2017
- Research and policy implications of a recently published controlled study in previously untreated haemophilia patients at high risk of inhibitor development. Haemophilia. 23:350-352. 2017
- Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. Haemophilia. 23:e170-e179. 2017
- What is the role for population pharmacokinetics in hemophilia?. International Journal of Pharmacokinetics. 2:125-136. 2017
- Oral contraceptive use is a provoking factor for venous thromboembolism. The BMJ. 357:j2073-j2073. 2017
- Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption. Journal of Medical Economics. 20:337-344. 2017
- A systematic review found that deviations from intention-to-treat are common in randomized trials and systematic reviews. Journal of Clinical Epidemiology. 84:37-46. 2017
- Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians.. ACP journal club. 166:430-437. 2017
- Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series. Haemophilia. 23:255-263. 2017
- Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians. ACP journal club. 166:279-279. 2017
- A critical appraisal of chronic kidney disease mineral and bone disorders clinical practice guidelines using the AGREE II instrument. International Urology and Nephrology. 49:273-284. 2017
- The current state of adverse event reporting in hemophilia. Expert Review of Hematology. 10:161-168. 2017
- Authors seldom report the most patient-important outcomes and absolute effect measures in systematic review abstracts. Journal of Clinical Epidemiology. 81:3-12. 2017
- Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA. PLoS ONE. 12:e0171028-e0171028. 2017
- GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. Journal of Clinical Epidemiology. 87:14-22. 2017
- Guideline for opioid therapy and chronic noncancer pain. CANADIAN MEDICAL ASSOCIATION JOURNAL. 189:E659-E666. 2017
- If You Build It, Who Will Come? A Description of User Characteristics and Experiences With the McMaster Optimal Aging Portal. Gerontology and Geriatric Medicine. 3:233372141773768-233372141773768. 2017
- Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data. Haemophilia. 23:e1-e7. 2017
- Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours. Thrombosis and Haemostasis. 117:589-594. 2017
- Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thrombosis and Haemostasis. 117:1023-1030. 2017
- The GRADE Working Group clarifies the construct of certainty of evidence. Journal of Clinical Epidemiology. 87:4-13. 2017
- The demographics, treatment characteristics and quality of life of adult people with haemophilia in China – results from the HERO study. Haemophilia. 23:89-97. 2017
- Thrombosis in Inherited Fibrinogen Disorders. Transfusion Medicine and Hemotherapy. 44:70-76. 2017
- VP57 Test-Retest Reliability Analysis Of The Patient Reported Outcomes Burdens And Experiences (PROBE) Study Questionnaire Test-Retest Reliability Analysis Of The PROBE Study Questionnaire. International Journal of Technology Assessment in Health Care. 33:174-175. 2017
- Development of a Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Study Protocol. JMIR Research Protocols. 5:e239-e239. 2016
- Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo). JMIR Research Protocols. 5:e232-e232. 2016
- Interpreting trial sequential analysis. Transfusion. 56:2918-2922. 2016
- Evaluation of the utility of the ISTH‐BAT in haemophilia carriers: a multinational study. Haemophilia. 22:912-918. 2016
- The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A. Expert Opinion on Drug Metabolism and Toxicology. 12:1313-1321. 2016
- Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal A systematic review and meta-analysis. Thrombosis and Haemostasis. 116:879-890. 2016
- User Experiences of the McMaster Optimal Aging Portal’s Evidence Summaries and Blog Posts: Usability Study. JMIR Human Factors. 3:e22-e22. 2016
- Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study. BMJ Open. 6:e010983-e010983. 2016
- Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 14:1668-1672. 2016
- Care models in the management of haemophilia: a systematic review. Haemophilia. 22:31-40. 2016
- Integrated multidisciplinary care for the management of chronic conditions in adults: an overview of reviews and an example of using indirect evidence to inform clinical practice recommendations in the field of rare diseases. Haemophilia. 22:41-50. 2016
- Methodology for the development of the NHF‐McMaster Guideline on Care Models for Haemophilia Management. Haemophilia. 22:17-22. 2016
- NHF‐McMaster Guideline on Care Models for Haemophilia Management. Haemophilia. 22:6-16. 2016
- Understanding intravenous iron ordering practices for inpatients and outpatients at a large academic institution. Transfusion Medicine Reviews. 30:147-147. 2016
- Understanding stakeholder important outcomes and perceptions of equity, acceptability and feasibility of a care model for haemophilia management in the US: a qualitative study. Haemophilia. 22:23-30. 2016
- The McMaster Optimal Aging Portal: Usability Evaluation of a Unique Evidence-Based Health Information Website. JMIR Human Factors. 3:e14-e14. 2016
- Report on the International Society for Laboratory Hematology Survey on guidelines to support clinical hematology laboratory practice. International Journal of Laboratory Hematology. 38:133-138. 2016
- Variation of DNA Fragmentation Levels During Density Gradient Sperm Selection for Assisted Reproduction Techniques. Medicine (United States). 95:e3624-e3624. 2016
- Haemophilia in a real‐world setting: the value of clinical experience in data collection. European Journal of Haematology. 96:3-9. 2016
- FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies. Haemophilia. 22:e36-e38. 2016
- A decisional model to individualize warfarin recommendations: Expected impact on treatment and outcome rates in a real-world population with atrial fibrillation. International Journal of Cardiology. 203:785-790. 2016
- Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study. Journal of Blood Medicine. Volume 7:239-253. 2016
- Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis. PLoS ONE. 11:e0156891-e0156891. 2016
- Erratum to Fischer et al. “Inhibitor development in nonsevere haemophilia across Europe” (Thromb Haemost 2015; 114: 670-675). Thrombosis and Haemostasis. 115:684-684. 2016
- Systematic reviews experience major limitations in reporting absolute effects. Journal of Clinical Epidemiology. 72:16-26. 2016
- Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. BMJ Open. 6:e010569-e010569. 2016
- Desmopressin acetate (DDAVP) for preventing and treating bleeding in people with mild or moderate haemophilia A. Clinical Respiratory Journal. 2015. 2015
- Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. Clinical Respiratory Journal. 2020:CD004449. 2015
- Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions. BMC Blood Disorders. 15:4. 2015
- A systematic review of definitions and reporting of bleeding outcome measures in haemophilia. Haemophilia. 21:731-735. 2015
- Cardiovascular disease (CVD) in Canadians with haemophilia: Age‐Related CVD in Haemophilia Epidemiological Research (ARCHER study). Haemophilia. 21:736-741. 2015
- Individualizing Factor Replacement Therapy in Severe Hemophilia. Seminars in Thrombosis and Hemostasis. 41:864-871. 2015
- Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta‐analysis of randomized controlled trials. Journal of Thrombosis and Haemostasis. 13:2012-2020. 2015
- Point of care ultrasonography in haemophilia care: recommendations for training and competency evaluation. Haemophilia. 21:828-831. 2015
- IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. Journal of Clinical Investigation. 125:3766-3781. 2015
- Inhibitor development in haemophilia according to concentrate. Thrombosis and Haemostasis. 113:968-975. 2015
- Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. Thrombosis and Haemostasis. 113:958-967. 2015
- Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A. Blood. 125:3816-3817. 2015
- Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. European Journal of Internal Medicine. 26:330-337. 2015
- Cardiovascular disease prevalence and relevance in haemophilia: a scoping review. Haemophilia. 21:e156-e166. 2015
- Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. Journal of Thrombosis and Haemostasis. 13:775-781. 2015
- Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. The BMJ. 350:h870-h870. 2015
- Pharmacokinetics of plasma‐derived vs. recombinant FVIII concentrates: a comparative study. Haemophilia. 21:204-209. 2015
- Commentary. Epidemiology. 26:27-29. 2015
- Developing methodology for the creation of clinical practice guidelines for rare diseases: A report from RARE-Bestpractices. Rare Diseases. 3:e1058463-e1058463. 2015
- Development of haemophilic arthropathy of the ankle: results of a Delphi consensus survey on potential contributory factors. Haemophilia. 21:116-123. 2015
- Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor. Thrombosis and Haemostasis. 114:56-64. 2015
- Haemophilia Experiences, Results and Opportunities (HERO) study: treatment‐related characteristics of the population. Haemophilia. 21:e26-e38. 2015
- Inhibitor development in non-severe haemophilia across Europe. Thrombosis and Haemostasis. 114:670-675. 2015
- Reporting, handling and assessing the risk of bias associated with missing participant data in systematic reviews: a methodological survey. BMJ Open. 5:e009368-e009368. 2015
- Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the HERO qualitative study. International Journal of Qualitative Studies on Health and Well-being. 10:28915-28915. 2015
- Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the HERO qualitative study.. International Journal of Qualitative Studies on Health and Well-being. 10:28915. 2015
- The GRADE evidence-to-decision framework: a report of its testing and application in 15 international guideline panels. Implementation Science. 11:93-93. 2015
- Effectiveness of Computerized Decision Support Systems Linked to Electronic Health Records: A Systematic Review and Meta-Analysis. American Journal of Public Health. 104:e12-e22. 2014
- Increasing the quantity and quality of searching for current best evidence to answer clinical questions: protocol and intervention design of the MacPLUS FS Factorial Randomized Controlled Trials. Implementation Science. 9:125. 2014
- Interventions for enhancing medication adherence. Clinical Respiratory Journal. 2014:CD000011. 2014
- Developing a two‐sided intervention to facilitate shared decision‐making in haemophilia: decision boxes for clinicians and patient decision aids for patients. Haemophilia. 20:800-806. 2014
- Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. European Journal of Internal Medicine. 25:847-852. 2014
- Non-invasive ventilation in the treatment of sleep-related breathing disorders: A review and update. Revista Portuguesa de Pneumologia (English Edition). 20:324-335. 2014
- Patient data meta‐analysis of Post‐Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF‐PFM. Haemophilia. 20:777-783. 2014
- Heart failure and chronic kidney disease in a registry of internal medicine wards. European Geriatric Medicine. 5:307-313. 2014
- Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Internal and emergency medicine. 9:723-734. 2014
- Stroke and Bleeding Risk Co-distribution in Real-world Patients with Atrial Fibrillation: The Euro Heart Survey. American Journal of Medicine. 127:979-986.e2. 2014
- Answering relevant research questions via careful observation of clinical practice: a fresh look at the old way forward. Haemophilia. 20:604-606. 2014
- Gender-differences in disease distribution and outcome in hospitalized elderly: Data from the REPOSI study. European Journal of Internal Medicine. 25:617-623. 2014
- Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature. 511:184-190. 2014
- Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. Haemophilia. 20:527-534. 2014
- First analysis of 10‐year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System. Haemophilia. 20:e251-e259. 2014
- Haemophilia Experiences, Results and Opportunities (HERO) Study: Influence of haemophilia on interpersonal relationships as reported by adults with haemophilia and parents of children with haemophilia. Haemophilia. 20:e287-e295. 2014
- Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin. International Journal of Laboratory Hematology. 36:341-351. 2014
- Joint WFH‐ISTH session: issues in clinical trial design. Haemophilia. 20:137-144. 2014
- PSY40 Indirect Comparison Of The Efficacy Of Recombinant Factor Viii Fc Fusion Protein And Other Factor Viii Products For ProphylaxisModeling The Effect Of Compliance. Value in Health. 17:a230. 2014
- PSY41 Indirect Comparison Of The Efficacy Of Recombinant Factor Ix Fc Fusion Protein And Other Factor Ix Products For Prophylaxis: Simulating The Effect Of Compliance On Real-World Effectiveness. Value in Health. 17:a230. 2014
- Patterns of tertiary prophylaxis in Canadian adults with severe and moderately severe haemophilia B. Haemophilia. 20:e199-e204. 2014
- Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B. Clinical Respiratory Journal. 2015:CD010561. 2014
- The haemophilia certification system in Canada.. Blood Transfusion. 12 Suppl 3:e531-e541. 2014
- Ruling out DVT using the Wells rule and a D-dimer test. The BMJ. 348:g1637-g1637. 2014
- Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity. Haemophilia. 20:200-206. 2014
- A methodological survey of the analysis, reporting and interpretation of Absolute Risk ReductiOn in systematic revieWs (ARROW): a study protocol (vol 2, 113, 2013). Systematic Reviews. 3:113. 2014
- Erratum to: A methodological survey of the analysis, reporting and interpretation of Absolute Risk ReductiOn in systematic revieWs (ARROW): a study protocol. Systematic Reviews. 3:76-76. 2014
- Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographics. Haemophilia. 20:44-51. 2014
- Impact of missing participant data for dichotomous outcomes on pooled effect estimates in systematic reviews: a protocol for a methodological study. Systematic Reviews. 3:137-137. 2014
- Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis. Thrombosis and Haemostasis. 111:172-179. 2014
- High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance. Journal of Hematology and Oncology. 6:63. 2013
- Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation. European Journal of Internal Medicine. 24:800-806. 2013
- Drug–drug interactions in a cohort of hospitalized elderly patients. Pharmacoepidemiology and Drug Safety. 22:1054-1060. 2013
- Erratum to “Small intestinal bacterial overgrowth and warfarin dose requirement variability” [Thromb. Res. 126 (1) (2010) 12–17]. Thrombosis Research. 132:e167-e167. 2013
- Inhibitor development in previously treated hemophilia A patients: a systematic review, meta‐analysis, and meta‐regression. Journal of Thrombosis and Haemostasis. 11:1655-1662. 2013
- Prevalence of potentially inappropriate medications in a cohort of hospitalized elderly: Results from the REPOSI study. European Geriatric Medicine. 4:s10. 2013
- Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. Internal and emergency medicine. 8:509-520. 2013
- Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B. Cochrane Database of Systematic Reviews. 2013. 2013
- The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters. Haemophilia. 19:351-354. 2013
- Factor VIII Products and Inhibitors in Severe Hemophilia A. New England Journal of Medicine. 368:1456-1457. 2013
- Factor VIII Products and Inhibitors in Severe Hemophilia A REPLY. New England Journal of Medicine. 368:1457-1457. 2013
- Factor VIII products and inhibitors in severe hemophilia A.. New England Journal of Medicine. 368:1456. 2013
- Adverse Clinical Events and Mortality During Hospitalization and 3 Months After Discharge in Cognitively Impaired Elderly Patients. The journals of gerontology. Series A, Biological sciences and medical sciences. 68:419-425. 2013
- Haemophilia at various stages of life: design of new therapeutic strategies through an interactive course--the Kogeniale project.. Blood Transfusion. 11:272-280. 2013
- Management of Patients With Unprovoked Venous Thromboembolism: An Evidence-Based and Practical Approach. Current Treatment Options in Cardiovascular Medicine. 15:224-239. 2013
- Patient-level compared with study-level meta-analyses demonstrate consistency of D-dimer as predictor of venous thromboembolic recurrences. Journal of Clinical Epidemiology. 66:415-425. 2013
- Association of Anticholinergic Burden with Cognitive and Functional Status in a Cohort of Hospitalized Elderly: Comparison of the Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale. Drugs and Aging. 30:103-112. 2013
- Clinical validation of a new algorithm for computerized dosing of vitamin K antagonist therapy: a retrospective simulation study. Internal and emergency medicine. 8:55-63. 2013
- Comparison of Disease Clusters in Two Elderly Populations Hospitalized in 2008 and 2010. Gerontology. 59:307-315. 2013
- Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study. BioMed Research International. 2013:1-7. 2013
- Risk factors for hospital readmission of elderly patients. European Journal of Internal Medicine. 24:45-51. 2013
- Ten-Year Canadian National Prospective Data On Utilization of Anti-Hemophilic Concentrates: Indications and Trends. Blood. 120:1186-1186. 2012
- Uncertainties in baseline risk estimates and confidence in treatment effects. The BMJ. 345:e7401-e7401. 2012
- Applicability of the AGREE II Instrument in Evaluating the Development Process and Quality of Current National Academy of Clinical Biochemistry Guidelines. Clinical Chemistry. 58:1426-1437. 2012
- Summarizing the theoretical foundation for hospital communication research: a scoping review of interdisciplinary literature 2012
- Clotting factor concentrate switching and inhibitor development in hemophilia A. Blood. 120:720-727. 2012
- Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). Journal of Thrombosis and Haemostasis. 10:1019-1025. 2012
- Psychosocial aspects of haemophilia: a systematic review of methodologies and findings. Haemophilia. 18:e101-e114. 2012
- Prevalence and characteristics of antidepressant drug prescriptions in older Italian patients. International Psychogeriatrics. 24:606-613. 2012
- Central nervous system bleeding in patients with rare bleeding disorders. Haemophilia. 18:34-38. 2012
- Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors. Haemophilia. 18:39-45. 2012
- Association between clusters of diseases and polypharmacy in hospitalized elderly patients: Results from the REPOSI study. European Journal of Internal Medicine. 22:597-602. 2011
- Individual participant data meta-analyses compared with meta-analyses based on aggregate data. Trials. 12:a57. 2011
- Indoleamine 2,3-Dioxygenase and Peripheral Tolerance to Exogenous Factor VIII: A Multi-Centre Pilot Study. Blood. 118:26. 2011
- Predicting Disease Recurrence in Patients with Previous Unprovoked Venous Thromboembolism: The DASH Prediction Score. Blood. 118:544. 2011
- Concentrate‐related inhibitor risk: is a difference always real?. Journal of Thrombosis and Haemostasis. 9:2176-2179. 2011
- Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: The extended DACUS study. American Journal of Hematology. 86:914-917. 2011
- Impact of Persistent Antiphospholipid Antibodies on Risk of Incident Symptomatic Thromboembolism in Children: A Systematic Review and Meta-Analysis. Seminars in Thrombosis and Hemostasis. 37:802-809. 2011
- Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database of Systematic Reviews. 9:CD003429. 2011
- In‐hospital death according to dementia diagnosis in acutely ill elderly patients: the REPOSI study. International Journal of Geriatric Psychiatry. 26:930-936. 2011
- The association between venous thromboembolism and physical inactivity in everyday life. The BMJ. 343:d3865-d3865. 2011
- Management of Inheritedvon Willebrand Disease in Italy: Results from the Retrospective Study on 1234 Patients. Seminars in Thrombosis and Hemostasis. 37:511-521. 2011
- Commentary. Annals of Internal Medicine. 154:31-36. 2011
- The Wells rule and a primary care rule were useful for ruling out deep venous thrombosis in primary care. ACP journal club. 154:JC6-JC6. 2011
- More about optimal choices in cardioembolism prevention. European Journal of Internal Medicine. 22:e19-e19. 2011
- Assessment of Recurrence Risk After Unprovoked Venous Thromboembolism. ACP journal club. 154:644-644. 2011
- Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. European Journal of Clinical Pharmacology. 67:507-519. 2011
- Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. European Journal of Internal Medicine. 22:205-210. 2011
- Referat zu: Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. Vasomed. 23:97-98. 2011
- Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. The BMJ. 342:d813-d813. 2011
- Clinical efficacy and safety of moroctocog alfa. Clinical Investigation. 1:305-316. 2011
- Recombinant Factor VIIa Concentrate versus Plasma-derived Concentrates for the Treatment of Acute Bleeding Episodes in Persons with Haemophilia and Inhibitors. European Oncology and Haematology. 07:140. 2011
- Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy.. Blood Transfusion. 9:60-69. 2011
- Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. European Journal of Internal Medicine. 21:516-523. 2010
- A Predictive Model for the Development of High-Responding Inhibitor In Children with Severe and Moderate Hemophilia A- Results of a Multicenter Cohort Study. Blood. 116:710. 2010
- Clinical Efficacy and Safety Versus Biological Response of Desmopressin (DDAVP) In Inherited Von Willebrand Disease (VWD) Types 1 and 2: Initial Results From the International Study Group on DDAVP In VWD In a Cohort of 229 Patients. Blood. 116:238. 2010
- Impact of Persistent Antiphospholipid Antibodies on Symptomatic Thromboembolism In Children: A Systematic Review & Meta-Analysis [Observational Studies]. Blood. 116:3169-3169. 2010
- Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient‐level meta‐analysis. Journal of Thrombosis and Haemostasis. 8:2436-2442. 2010
- Risk of Recurrence After a First Episode of Symptomatic Venous Thromboembolism Provoked by a Transient Risk Factor. JAMA Internal Medicine. 170:1710-1716. 2010
- A 9-factor score predicted 2-year risk for bleeding in outpatients with, or at high risk for, atherothrombosis. ACP journal club. 153:JC4-JC4. 2010
- Patient-Level Meta-analysis: Effect of Measurement Timing, Threshold, and Patient Age on Ability ofd-Dimer Testing to Assess Recurrence Risk After Unprovoked Venous Thromboembolism. ACP journal club. 153:523-523. 2010
- Residual Vein Thrombosis and D-Dimer for Optimizing Duration of Anticoagulation in Idiopathic Deep Vein Thrombosis. Current Pharmaceutical Design. 16:3483-3486. 2010
- Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. Journal of Thrombosis and Haemostasis. 8:2313-2315. 2010
- In-Hospital Death and Adverse Clinical Events in Elderly Patients According to Disease Clustering: The REPOSI Study. Rejuvenation Research. 13:469-477. 2010
- Small intestinal bacterial overgrowth and warfarin dose requirement variability. Thrombosis Research. 126:12-17. 2010
- Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review. Journal of Thrombosis and Haemostasis. 8:1256-1265. 2010
- Mortality and causes of death in Italian persons with haemophilia, 1990–2007. Haemophilia. 16:437-446. 2010
- Impact of Thrombophilia on Risk of Arterial Ischemic Stroke or Cerebral Sinovenous Thrombosis in Neonates and Children. Circulation. 121:1838-1847. 2010
- Influenza Vaccination and Vitamin K Antagonist Treatment. JAMA Internal Medicine. 170:609-616. 2010
- Selective outcome reporting: telling and detecting true lies. The state of the science. Internal and emergency medicine. 5:151-155. 2010
- Residual Venous Obstruction, alone and in Combination with D-Dimer, as a Risk Factor for Recurrence after Anticoagulation Withdrawal following a First Idiopathic Deep Vein Thrombosis in the Prolong Study. European Journal of Vascular and Endovascular Surgery. 39:356-365. 2010
- Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. Clinical Respiratory Journal. CD004888. 2010
- Bone mineral density in haemophilia patients. Thrombosis and Haemostasis. 103:596-603. 2010
- Response: Comparing joint arthroplasties in severe hemophilia A with severe hemophilia B. Blood. 114:4907-4908. 2009
- Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies.. Blood. 114:3993-3993. 2009
- Prevalence and Determinants of Bleeding in Severe Von Willebrand Disease Type 3: Results of Retro/Prospective Studies in a Cohort of 105/52 Italian Patients.. Blood. 114:3494. 2009
- Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.. Blood. 114:3154. 2009
- Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research. 124:e1-e5. 2009
- Peginterferon Plus Ribavirin for Chronic Hepatitis C in Patients With Human Immunodeficiency Virus. American Journal of Gastroenterology. 104:2335-2341. 2009
- Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. American Journal of Hematology. 84:584-588. 2009
- Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood. 114:779-784. 2009
- Clinical trials and haemophilia: does the Bayesian approach make the ideal and desirable good friends?. Haemophilia. 15:900-903. 2009
- Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. Journal of Thrombosis and Haemostasis. 7:780-786. 2009
- Performance of recalibrated ReFacto^® laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one‐stage assays after infusion of recalibrated ReFacto^® (B‐domain deleted recombinant factor VIII). Haemophilia. 15:779-787. 2009
- Errata. Haemophilia. 15:637-637. 2009
- Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis (vol 14, pg 444, 2008). Haemophilia. 15:637-637. 2009
- Patients’, physicians’, and pharmacists’ preferences towards coagulation factor concentrates to treat haemophilia with inhibitors: results from the COHIBA Study. Haemophilia. 15:473-486. 2009
- Venous Thromboembolism Recurrence after a First Episode of Provoked Venous Thrombosis Due to a Transient Risk Factor. A Systematic Review of the Literature. Blood. 112:3029. 2008
- Audit of the clinical use of fresh-frozen plasma in Umbria: study design and results of the pilot phase.. Blood Transfusion. 6:211-219. 2008
- Selecting references that match constructs: the difficult job of citing the parachute hyperbole. Internal and emergency medicine. 3:151-154. 2008
- Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia. 14:444-453. 2008
- Interventions for enhancing medication adherence. Clinical Respiratory Journal. CD000011. 2008
- Iatrogenic causes of an ICH. European Journal of Anaesthesiology. 25:8-11. 2008
- Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting. Thrombosis and Haemostasis. 99:52-58. 2008
- The good use of plasma. A critical analysis of five international guidelines.. Blood Transfusion. 6:18-24. 2008
- Seizures, headache and thrombocytopenia: diagnosis and treatment do not always come in a standard sequence. Internal and emergency medicine. 2:202-206. 2007
- RANDOMISED, OPEN, PROSPECTIVE, MULTICENTER PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ACTIVATED RECOMBINANT FACTOR VIIA (NOVOSEVEN) IN ACUTE INTRACEREBRAL HAEMORRHAGE IN PATIENTS TREATED WITH ORAL ANTICOAGULANT OR ANTIPLATELET AGENTS. Journal of Thrombosis and Haemostasis. 5:p-t-162-p-t-162. 2007
- Chronic Prostatitis. New England Journal of Medicine. 356:423-424. 2007
- Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type1 diabetic patients. Thrombosis and Haemostasis. 98:635-641. 2007
- Thrombophilia and Cerebral Vein Thrombosis. Frontiers of Neurology and Neuroscience. 23:55-76. 2007
- Influenza vaccination in patients on long-term anticoagulant therapy. Vaccine. 24:6624-6628. 2006
- d-Dimer Testing to Determine the Duration of Anticoagulation Therapy. New England Journal of Medicine. 355:1780-1789. 2006
- Are placebo‐controlled trials ethical in areas where current guidelines recommend therapy? No. Journal of Thrombosis and Haemostasis. 4:2133-2136. 2006
- High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C.. Haematologica. 91:1367-1371. 2006
- Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database of Systematic Reviews. CD003429. 2006
- Can evidence harm? Certainly not hemophilia treatment and community. Journal of Thrombosis and Haemostasis. 4:505-506. 2006
- Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma‐derived solvent‐detergent factor VIII concentrate. Haemophilia. 12:128-132. 2006
- Intracranial Haemorrhage in Patients on Antithrombotics: Clinical Presentation and Determinants of Outcome in a Prospective Multicentric Study in Italian Emergency Departments. Cerebrovascular Diseases. 22:286-293. 2006
- High Efficacy of Combination Therapy with Pegylated Interferon and Ribavirin in Hemophiliacs with Chronic Hepatitis C.. Blood. 106:3219. 2005
- Differences between patients’, physicians’ and pharmacists’ preferences for treatment products in haemophilia: a discrete choice experiment. Haemophilia. 11:589-597. 2005
- Performance Comparison of Three Assay Methods Used in Fasting and Postmethionine Load Plasma Homocysteine Determinations From Patients With Vascular Disease. American Journal of Clinical Pathology. 124:675-681. 2005
- Performance comparison of three assay methods used in fasting and postmethionine load plasma homocysteine determinations from patients with vascular disease. American Journal of Clinical Pathology. 124:675-681. 2005
- Safety and Efficacy of Ximelagatran: Meta-Analysis of the Controlled Randomized Trials for the Prophylaxis or Treatment of Venous Thromboembolism. Current Pharmaceutical Design. 11:3893-3918. 2005
- Successful treatment with rFVIIa of spontaneous intracerebral hemorrhage in a patient with mechanical prosthetic heart valves. International Journal of Laboratory Hematology. 27:283-285. 2005
- Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database of Systematic Reviews. CD003429. 2005
- Interventions to enhance medication adherence. Cochrane Database of Systematic Reviews. 2005
- Corrigenda. Journal of Thrombosis and Haemostasis. 2:1504-1504. 2004
- Prevention of venous thromboembolism after major orthopedic surgery: summing up evidence about old and new antithrombotic agents (vol 2, pg 1055, 2004). Journal of Thrombosis and Haemostasis. 2:1504-1504. 2004
- Prevention of venous thromboembolism after major orthopedic surgery: summing up evidence about old and new antithrombotic agents. Journal of Thrombosis and Haemostasis. 2:1055-1057. 2004
- Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behçet's disease and deep vein thrombosis. Arthritis and Rheumatism. 51:177-183. 2004
- Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. Journal of Thrombosis and Haemostasis. 1:1906-1913. 2003
- Applied pharmacoeconomics: considerations to drive the choice of a prophylactic antithrombotic regimen. Journal of Thrombosis and Haemostasis. 1:881-883. 2003
- Flow cytometric measurement of intracellular IFN-gamma induction in aged subjects before and after parenteral influenza vaccination.. Developments in Biologicals. 115:55-59. 2003
- Low-Molecular-Weight Heparin and Cancer Survival: Review of the Literature and Pooled Analysis of 1,726 Patients Treated for at Least Three Months. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 33:197-201. 2003
- Intracranial bleeding: epidemiology and relationships with antithrombotic treatment in 241 cerebral hemorrhages in Reggio Emilia.. Haematologica. 87:948-956. 2002
- Influenza A Virus Specific T Cell Immunity in Humans during Aging. Virology. 299:100-108. 2002
- Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis. New England Journal of Medicine. 345:165-169. 2001
- Low-Molecular-Weight and Unfractionated Heparin for Prevention of Venous Thromboembolism in Neurosurgery. JAMA Internal Medicine. 160:2327-2327. 2000
- Mesenteric-portal Vein Thrombosis in a Patient with Hyperhomocysteinemia and Heterozygous for 20210A Prothrombin Allele. Thrombosis and Haemostasis. 84:358-359. 2000
- Miconazole Oral Gel Potentiates Warfarin Anticoagulant Activity. Thrombosis and Haemostasis. 83:794-795. 2000
- Enoxaparin Plus Compression Stockings Compared With Compression Stockings Alone in the Prevention of Venous Thromboembolism After Elective Neurosurgery. Investigative Urology. 162:1565-1566. 1999
- Enoxaparin Plus Compression Stockings Compared With Compression Stockings Alone in the Prevention of Venous Thromboembolism After Elective Neurosurgery. Investigative Urology. 162:1565-1566. 1999
- Withdrawal of warfarin after deep vein thrombosis. Blood Coagulation and Fibrinolysis. 10:291-296. 1999
- Enoxaparin Plus Compression Stockings Compared With Compression Stockings Alone in the Prevention of Venous Thromboembolism After Elective Neurosurgery. Obstetrical and Gynecological Survey. 53:681-682.. 1998
- Enoxaparin plus Compression Stockings Compared with Compression Stockings Alone in the Prevention of Venous Thromboembolism after Elective Neurosurgery. New England Journal of Medicine. 339:80-85. 1998
- Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. Blood Coagulation and Fibrinolysis. 8:216-222. 1997
- Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group.. Blood Coagulation and Fibrinolysis. 8:216-222. 1997
- Pharmacokinetic Optimisation of the Treatment of Deep Vein Thrombosis. Clinical Pharmacokinetics. 32:145-172. 1997
- Effect of Dermatan Sulphate on Activated Partial Thromboplastin Time Determined with Different Reagents. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 27:85-90. 1997
- Post-discharge deep-vein thrombosis after orthopaedic surgery. The Lancet. 348:1180-1180. 1996
- Increased Plasma Levels of Tissue Factor Pathway Inhibitor (TFPI) after n-3 Polyunsaturated Fatty Acids Supplementation in Patients with Chronic Atherosclerotic Disease. Thrombosis and Haemostasis. 75:395-400. 1996
- Post Discharge Clinically Overt Venous Thromboembolism in Orthopaedic Surgery Patients with Negative Venography -an Overview Analysis. Thrombosis and Haemostasis. 76:0887-0892. 1996
- Prolonged Antithrombin Activity of Low-Molecular-Weight Heparins. Circulation. 92:2819-2824. 1995
- Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction.. Translational Research. 125:212-221. 1995
- Dermatan sulphate in heparin-induced thrombocytopenia. The Lancet. 344:1295-1296. 1994
- Plasma Thrombin Neutralization Assay: Pharmacokinetic Applications. Seminars in Thrombosis and Hemostasis. 20:266-273. 1994
- Antipyretic analgesics. Side Effects of Drugs Annual. 18:90-98. 1994
- Streptokinase and rt-PA activate platelets by a different way: Implications on the rethrombosis rate after their administration in myocardial infarction. Fibrinolysis and Proteolysis. 8:74. 1994
- Fibrinogen degradation products generation is the major determinant of platelet inhibition induced by plasminogen activators in platelet-rich plasma. Fibrinolysis and Proteolysis. 7:379-385. 1993
- Thrombolytic and haemorrhagic effects of bolus doses of rt-PA and A hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). Thrombosis Research. 70:s91. 1993
- PB2629: LATE DIAGNOSIS OF TWO ADULT SIBLINGS WITH BERNARD SOULIER SYNDROME (BSS). HemaSphere. 7:e63685a6.
- PB2647: USE OF EMICIZUMAB FOR THE TREATMENT OF ACQUIRED HEMOPHILIA A: A SYSTEMATIC REVIEW. HemaSphere. 7:e391797d.
- Psychological interventions for people with hemophilia. Clinical Respiratory Journal.
- Reflections on the Canadian Bleeding Disorders Registry: Lessons Learned and Future Perspectives. Canadian Journal of Health Technologies. 2.
preprints